Amicus Therapeutics to Participate in BIO CEO & Investor Conference and Leerink Swann Global Healthcare Conference

CRANBURY, N.J., Feb. 4, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in two upcoming conferences in February.

15th Annual BIO CEO & Investor Conference in New York, NY

Mr. Crowley will participate in a panel, "Orphan Drugs: Making Rare Diseases Rarer," to be held during the 15th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 9:00 a.m. ET in New York, NY. More information about this panel can be found at http://www.bio.org/node/14521.

Leerink Swann Global Healthcare Conference

Mr. Crowley will present a corporate overview during the Leerink Swann Global Healthcare Conference 2013 in New York, NY on Wednesday, February 13, 2013 at 12:00 p.m. ET. A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of human genetic diseases. Amicus' late-stage programs for lysosomal storage disorders include migalastat HCl monotherapy in Phase 3 for Fabry disease; migalastat HCl co-administered with enzyme replacement therapy (ERT) in Phase 2 for Fabry disease; and AT2220 co-administered with ERT in Phase 2 for Pompe disease.


CONTACT: Amicus Therapeutics Sara Pellegrino (609) 662-5044 spellegrino@amicusrx.comSource:Amicus Therapeutics, Inc.